C4 Therapeutics (CCCC) financial statements
C4 Therapeutics reported revenue of $36M in fiscal 2025, down 5.9% a year over 4 years.
Net income was -$105M.
Free cash flow was -$99M, and the company returned $193,000 in net buybacks.
The diluted share count rose 5942% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from C4 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $46M | $31M | $21M | $36M | $36M |
| Research and development | $48M | $78M | $95M | $118M | $118M | $111M | $104M |
| Selling, general and admin | $9M | $15M | $33M | $43M | $42M | $42M | $36M |
| Operating income | -$35M | -$60M | -$82M | -$130M | -$139M | -$120M | -$115M |
| Pre-tax income | -$33M | -$67M | -$84M | -$128M | -$131M | -$105M | -$105M |
| Income tax | $804,000 | -$626,000 | $0 | $0 | $1M | $131,000 | $121,000 |
| Net income | -$34M | -$66M | -$84M | -$128M | -$132M | -$105M | -$105M |
| EPS (diluted) | -$31.03 | -$5.83 | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Diluted shares | 1M | 11M | 46M | 49M | 50M | 69M | 83M |
| Operating margin | — | — | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% |
| Net margin | — | — | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
Balance sheet
Fiscal years, from C4 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $91M | $372M | $452M | $337M | $282M | $267M | $297M |
| Receivables | $5M | $4M | $6M | $1M | $12M | $3M | $2M |
| Total current assets | $97M | $381M | $326M | $288M | $271M | $258M | $258M |
| Property, plant and equipment | $4M | $3M | $3M | $7M | $7M | $6M | $5M |
| Total assets | $118M | $400M | $507M | $431M | $376M | $350M | $359M |
| Total current liabilities | $34M | $44M | $51M | $45M | $43M | $45M | $33M |
| Long-term debt | — | $10M | $11M | $9M | $0 | — | — |
| Total liabilities | $119M | $119M | $117M | $142M | $130M | $134M | $102M |
| Shareholders' equity | -$112M | $281M | $390M | $289M | $246M | $216M | $257M |
| Net debt | -$91M | -$172M | -$65M | -$18M | -$127M | -$55M | -$75M |
Cash flow
Fiscal years, from C4 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $56M | -$67M | -$87M | -$106M | -$107M | -$65M | -$99M |
| Capital spending | $1M | $650,000 | $1M | $5M | $2M | $180,000 | $607,000 |
| Free cash flow | $54M | -$68M | -$88M | -$111M | -$109M | -$65M | -$99M |
| Stock-based compensation | $2M | $3M | $22M | $30M | $27M | $30M | $19M |
| Share buybacks (net) | -$30,000 | -$194,000 | — | $0 | -$110,000 | -$194,000 | -$193,000 |
| Free cash flow margin | — | — | -192.7% | -358.4% | -523.0% | -183.6% | -276.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CCCC.
Open CCCC in InvestinglyQuestions
What was C4 Therapeutics's revenue in 2025?
$36M in fiscal 2025, from its 10-K filing.
How much free cash flow does C4 Therapeutics generate?
-$99M in fiscal 2025 (operating cash flow minus capital spending).
From C4 Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.